Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Elixir Department: SOP for Solubility Profiling of Active Ingredients – V 2.0

Posted on By

Elixir Department: SOP for Solubility Profiling of Active Ingredients – V 2.0

Standard Operating Procedure for Solubility Profiling of Active Ingredients in Elixir Formulations

Department Elixir Department
SOP No. SOP/ELX/050/2025
Supersedes SOP/ELX/050/2022
Page No. Page 1 of 8
Issue Date 11/04/2025
Effective Date 15/04/2025
Review Date 11/04/2026

1. Purpose

To outline the procedure for conducting solubility profiling of active pharmaceutical ingredients (APIs) in various solvents and co-solvent systems during elixir formulation development to aid in selection of suitable solubilizing agents.

2. Scope

This SOP is applicable to formulation and analytical development teams performing solubility profiling of APIs for elixir dosage forms in the Elixir Department. It includes solubility assessment in purified water, alcohols, glycols, surfactants, and buffer systems.

3. Responsibilities

  • Formulation Scientist:
    • Design and perform solubility studies as per protocol.
  • Analytical Scientist:
    • Analyze solubility samples using validated analytical methods.
  • QA Officer:
    • Review protocols, results, and ensure compliance with applicable regulatory standards.
See also  Elixir Department: SOP for Dispensing Active Pharmaceutical Ingredients for Elixirs - V 2.0

4. Accountability

The R&D Head is accountable for ensuring that solubility profiling is conducted using scientifically sound and validated approaches prior to formulation development.

5. Procedure

5.1 Preparation

  1. Ensure
all reagents and solvents (e.g., water, ethanol, propylene glycol) are of analytical grade and documented in the study plan.
  • Label all glassware and containers clearly and maintain controlled temperature during the study (25°C ± 2°C unless otherwise specified).
  • 5.2 Selection of Solvents

    1. Shortlist solvents and co-solvents based on:
      • Regulatory acceptability (as per IIG database, GRAS status)
      • Chemical compatibility with the API
      • Formulation requirement (oral liquid)

    5.3 Solubility Determination Procedure

    1. Weigh excess API (approx. 100 mg) into screw-capped vials.
    2. Add 10 mL of each solvent to separate vials.
    3. Stir at 25°C for 24 hours using magnetic stirrers or shaking water bath.
    4. Visually inspect and note clear/unclear solutions.
    5. Centrifuge or filter through 0.45 µm membrane filter.
    6. Quantify drug concentration in the supernatant using UV or HPLC method.

    5.4 Expression of Solubility

    1. Express solubility in terms of:
      • mg/mL
      • Parts of solvent required to dissolve 1 part of solute
    2. Classify solubility as per USP/NF:
      • Very soluble: <1 part solvent
      • Freely soluble: 1–10 parts
      • Sparingly soluble: 30–100 parts
      • Practically insoluble: >10,000 parts

    5.5 Reporting

    1. Document findings in the Solubility Profiling Report (Annexure-1).
    2. Prepare comparison table (Annexure-2) and attach instrument data sheets.
    3. QA to verify and archive final report before proceeding to formulation screening.

    6. Abbreviations

    • SOP: Standard Operating Procedure
    • API: Active Pharmaceutical Ingredient
    • QA: Quality Assurance
    • USP: United States Pharmacopeia
    • GRAS: Generally Recognized As Safe

    7. Documents

    1. Solubility Profiling Report (Annexure-1)
    2. Solubility Comparison Table (Annexure-2)
    3. Instrument Calibration Records (Annexure-3)

    8. References

    • ICH Q8 – Pharmaceutical Development
    • USP General Chapter <1230> – Solubility Classification
    • FDA Inactive Ingredient Database

    9. SOP Version

    Version: 2.0

    10. Approval Section

    Prepared By Checked By Approved By
    Signature
    Date
    Name
    Designation
    Department

    11. Annexures

    Annexure-1: Solubility Profiling Report

    API Name Solvent Temp (°C) Solubility (mg/mL) USP Class Remarks
    Drug A Propylene Glycol 25 85.6 Freely Soluble Suitable for use
    Drug A Water 25 4.3 Sparingly Soluble Requires co-solvent

    Annexure-2: Solubility Comparison Table

    Solvent Solubility (mg/mL) Classification
    Water 4.3 Sparingly Soluble
    Ethanol 56.1 Freely Soluble
    PG 85.6 Freely Soluble

    Annexure-3: Instrument Calibration Records

    Instrument Calibration Date Next Due Date Performed By
    UV Spectrophotometer 01/04/2025 01/10/2025 Ajay Mehta
    Analytical Balance 01/04/2025 01/07/2025 Manju Sharma

    Revision History:

    Revision Date Revision No. Revision Details Reason for Revision Approved By
    01/01/2024 1.0 Initial Version New SOP QA Head
    11/04/2025 2.0 Added Annexures and Solvent Classification Tables Process Standardization QA Head
    See also  Elixir Department: SOP for Handling Material Return Post Dispensing - V 2.0
    Elixers V 2.0 Tags:Elixir colorants, Elixir dosage form, Elixir filtration techniques, Elixir flavoring agents, Elixir formulation, Elixir GMP compliance, Elixir manufacturing process, Elixir manufacturing SOPs, Elixir packaging requirements, Elixir pharmacopoeial standards, Elixir preparation methods, Elixir preservatives, Elixir production equipment, Elixir quality control, Elixir regulatory guidelines, Elixir shelf life, Elixir stability testing, Elixir sterilization methods, Elixir storage conditions, Elixir sweetening agents, Elixir viscosity modifiers, Hydroalcoholic solutions, Medicated elixirs, Non-medicated elixirs, Pharmaceutical elixirs

    Post navigation

    Previous Post: Analytical Method Development: Limit Test for Chloride/Sulphate Development – V 2.0
    Next Post: API Manufacturing: SOP for Sampling of Viscous and Sticky Materials – V 2.0

    Standard Operating Procedures V 1.0

    • Aerosols
    • Analytical Method Development
    • Bioequivalence Bioavailability Study
    • Capsule Formulation
    • Clinical Studies
    • Creams
    • Data Integrity
    • Dental Dosage Forms
    • Drug Discovery
    • Environment, Health and Safety
    • Formulation Development
    • Gels
    • Good Distribution Practice
    • Good Warehousing Practices
    • In-Process Control
    • Injectables
    • Liquid Orals
    • Liposome and Emulsion Formulations
    • Lotions
    • Lyophilized Products
    • Maintenance Dept.
    • Medical Devices
    • Metered-Dose Inhaler
    • Microbiology Testing
    • Nanoparticle Formulation
    • Nasal Spray Formulations
    • Nebulizers
    • Ocular (Eye) Dosage Forms
    • Ointments
    • Otic (Ear) Dosage Forms
    • Pharmacovigilance
    • Powder & Granules
    • Purchase Departments
    • Quality Assurance
    • Quality Control
    • Raw Material Stores
    • Regulatory Affairs
    • Tablet Manufacturing
    • Rectal Dosage Forms
    • Transdermal Patches
    • Vaginal Dosage Forms
    • Validations and Qualifications

    Read SOPs in your Language:

     - 
    Bengali
     - 
    bn
    English
     - 
    en
    Gujarati
     - 
    gu
    Hindi
     - 
    hi
    Malayalam
     - 
    ml
    Marathi
     - 
    mr
    Punjabi
     - 
    pa
    Tamil
     - 
    ta
    Telugu
     - 
    te

    NEW! Revised SOPs – V 2.0

    • Aerosols V 2.0
    • Analytical Method Development V 2.0
    • API Manufacturing V 2.0
    • BA-BE Studies V 2.0
    • Biosimilars V 2.0
    • Capsules V 2.0
    • Creams V 2.0
    • Elixers V 2.0
    • Ointments V 2.0
    • Raw Material Warehouse V 2.0
    • Tablet Manufacturing V2.0

    New Publication: A must for All.

    Copyright © 2025 SOP Guide for Pharma.

    Powered by PressBook WordPress theme

    Go to mobile version